Leap Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Leap Therapeutics' es Doug Onsi , nombrado en Jan 2011, tiene una permanencia de 13.25 años. compensación anual total es $1.88M, compuesta por 33.8% salario y 66.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.29% de las acciones de la empresa, por valor de $236.40K. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 7.3 años, respectivamente.
Información clave
Doug Onsi
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 43.6% |
| Permanencia del CEO | 13.4yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?
Mar 13
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?
Nov 22Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05
Aug 12Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers
Jul 12Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
Jun 27Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation
May 01Leap Therapeutics: Waiting For One More Leap
Feb 18We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely
Jan 04Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
Nov 29Leap Therapeutics: All On The Line
Oct 13Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Sep 15Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Jun 01Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth
Mar 03Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?
Jan 27
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year
Dec 23Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)
Nov 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$53m |
| Dec 31 2023 | US$2m | US$669k | -US$81m |
| Sep 30 2023 | n/a | n/a | -US$81m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$2m | US$637k | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$42m |
| Dec 31 2021 | US$2m | US$596k | -US$41m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$2m | US$513k | -US$38m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$817k | US$400k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$22m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$682k | US$400k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$3m | US$397k | -US$30m |
Compensación vs. Mercado: La compensación total de Doug($USD1.88M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).
Compensación vs. Ingresos: La compensación de Doug ha sido consistente con los resultados de la empresa en el último año.
CEO
Doug Onsi (55 yo)
13.4yrs
Permanencia
US$1,534,507
Compensación
Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CFO, General Counsel | 13.4yrs | US$1.53m | 0.19% $ 162.0k | |
| Chief Operating Officer | 8.4yrs | US$1.00m | 0.013% $ 11.2k | |
| Chief Medical Officer | 4.2yrs | US$999.40k | 0.013% $ 11.0k | |
| Chief Scientific Officer | 1.2yrs | sin datos | sin datos | |
| Chief Manufacturing Officer | 4.2yrs | sin datos | 0.013% $ 11.0k | |
| VP and Head of Regulatory Affairs & Quality | 3.8yrs | sin datos | sin datos |
4.2yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de LPTX se considera experimentado (4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CFO, General Counsel | 4.3yrs | US$1.53m | 0.19% $ 162.0k | |
| Chairman | 13.4yrs | US$744.18k | 0.013% $ 11.2k | |
| Independent Director | 8.4yrs | US$126.62k | 0% $ 0 | |
| Lead Independent Director | 8.4yrs | US$188.86k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$118.24k | 0% $ 0 | |
| Independent Director | 8.4yrs | US$112.12k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$121.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 1.8yrs | US$112.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.4yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 3.4yrs | sin datos | sin datos |
7.4yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de LPTX se considera experimentada (7.3 años de antigüedad promedio).